Payment overview · 2025
General Payments
$1,047.14
61 reported records · 18 companies
Healthcare provider profile · identity verified
Jill G Bryant, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WAYCROSS, GA · NPI 1306820741
Verified facts
What the public records show
CMS Open Payments records show Jill G Bryant, MD received $1,047.14 in general payments during 2025 across 61 reported records.
Novo Nordisk Inc accounted for 15.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti, Rybelsus, Tirosint, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
IBSA Pharma Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tirosint as an associated drug or biological on 6755 records involving 4085 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tirosint by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 253 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $157.06 | 15.0% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $127.50 | 12.2% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $104.45 | 10.0% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $90.19 | 8.6% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $89.83 | 8.6% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $73.66 | 7.0% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $54.18 | 5.2% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $51.79 | 5.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.70 | 4.6% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $46.97 | 4.5% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $38.53 | 3.7% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $36.10 | 3.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.02 | 3.1% | 2 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $20.63 | 2.0% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $20.09 | 1.9% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $19.84 | 1.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $19.39 | 1.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.21 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,047.14 | 61 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $110.75 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $110.75 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $105.06 | 8 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $104.45 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $73.66 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $73.00 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $57.89 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $54.18 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $52.00 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $51.79 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $51.39 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $49.77 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $47.70 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $46.97 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $38.53 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $36.10 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $32.30 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $32.30 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $32.30 | 2 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $20.63 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $20.63 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $20.63 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 15 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 253 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 106 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 122 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 158 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Tirosint tirosint |
2025 | Tirosint | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
40 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
106 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| IBSA Pharma Inc. Exact reporting entity; no affiliate inference |
2025 | Tirosint open payments reported associated product |
CMS Open Payments — General Payments 6755 supporting records · 4085 recipient NPIs · example record 1211687357 |
Tirosint · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
106 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
122 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
158 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
253 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1354 | 232 |
| Atorvastatin Calcium | Atorvastatin Calcium | 730 | 132 |
| Omeprazole | Omeprazole | 595 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 564 | 125 |
| Metoprolol Succinate | Metoprolol Succinate | 561 | 100 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 560 | 123 |
| Gabapentin | Gabapentin | 539 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 480 | 86 |
| Losartan Potassium | Losartan Potassium | 476 | 117 |
| Potassium Chloride | Potassium Chloride | 458 | 74 |
| Lisinopril | Lisinopril | 417 | 88 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 396 | 83 |
| Escitalopram Oxalate | Escitalopram Oxalate | 386 | 45 |
| Furosemide | Furosemide | 363 | 81 |
| Hydrochlorothiazide | Hydrochlorothiazide | 347 | 80 |
| Simvastatin | Simvastatin | 339 | 92 |
| Clopidogrel | Clopidogrel Bisulfate | 327 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 277 | 42 |
| Eliquis | Apixaban | 253 | 39 |
| Sertraline Hcl | Sertraline Hcl | 250 | 34 |
| Carvedilol | Carvedilol | 237 | 55 |
| Donepezil Hcl | Donepezil Hcl | 226 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 220 | 37 |
| Metformin Hcl | Metformin Hcl | 214 | 62 |
| Meloxicam | Meloxicam | 207 | 56 |
| Montelukast Sodium | Montelukast Sodium | 200 | 43 |
| Tramadol Hcl | Tramadol Hcl | 198 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 194 | 33 |
| Alprazolam | Alprazolam | 178 | 55 |
| Memantine Hcl | Memantine Hcl | 174 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 173 | 35 |
| Famotidine | Famotidine | 170 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 165 | 21 |
| Azithromycin | Azithromycin | 163 | 116 |
| Synthroid | Levothyroxine Sodium | 162 | 37 |
| Buspirone Hcl | Buspirone Hcl | 160 | 17 |
| Ozempic | Semaglutide | 158 | 35 |
| Rivastigmine | Rivastigmine Tartrate | 157 | suppressed |
| Glimepiride | Glimepiride | 148 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 143 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 134 | suppressed |
| Lorazepam | Lorazepam | 133 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 48 |
| Citalopram Hbr | Citalopram Hydrobromide | 123 | 23 |
| Spironolactone | Spironolactone | 123 | 21 |
| Mounjaro | Tirzepatide | 122 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 119 | 17 |
| Cefdinir | Cefdinir | 107 | 81 |
| Jardiance | Empagliflozin | 106 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 106 | 14 |
| Prednisone | Prednisone | 105 | 51 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 104 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 41 |
| Humalog Kwikpen U-100 | Insulin Lispro | 94 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 93 | 43 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 91 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 88 | 68 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 87 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 83 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 81 | suppressed |
| Bupropion Xl | Bupropion Hcl | 79 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 77 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 76 | 15 |
| Finasteride | Finasteride | 75 | suppressed |
| Levetiracetam | Levetiracetam | 75 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 25 |
| Allopurinol | Allopurinol | 74 | 19 |
| Ezetimibe | Ezetimibe | 73 | 16 |
| Januvia | Sitagliptin Phosphate | 73 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 72 | 24 |
| Nifedipine Er | Nifedipine | 72 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 71 | 40 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 71 | 54 |
| Bumetanide | Bumetanide | 68 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 64 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 63 | 23 |
| Celecoxib | Celecoxib | 62 | 15 |
| Methocarbamol | Methocarbamol | 62 | suppressed |
| Atenolol | Atenolol | 61 | 15 |
| Ranolazine Er | Ranolazine | 61 | suppressed |
| Olanzapine | Olanzapine | 60 | suppressed |
| Mirtazapine | Mirtazapine | 59 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 59 | 13 |
| Alendronate Sodium | Alendronate Sodium | 57 | 12 |
| Methylprednisolone | Methylprednisolone | 57 | 37 |
| Ramipril | Ramipril | 57 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 56 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 13 |
| Amoxicillin | Amoxicillin | 55 | 39 |
| Potassium Citrate Er | Potassium Citrate | 55 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 15 |
| Trulicity | Dulaglutide | 54 | 12 |
| Estradiol | Estradiol | 53 | 16 |
| Liothyronine Sodium | Liothyronine Sodium | 53 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 53 | suppressed |
| Xarelto | Rivaroxaban | 52 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 23 |
| Pregabalin | Pregabalin | 51 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 50 | suppressed |
| Temazepam | Temazepam | 50 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 48 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 48 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 12 |
| Valsartan | Valsartan | 45 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Fluconazole | Fluconazole | 43 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Anastrozole | Anastrozole | 40 | suppressed |
| Nystatin | Nystatin | 40 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 40 | suppressed |
| Prolia | Denosumab | 40 | 24 |
| Valacyclovir | Valacyclovir Hcl | 40 | 19 |
| Cephalexin | Cephalexin | 39 | 33 |
| Sevelamer Carbonate | Sevelamer Carbonate | 39 | suppressed |
| Risperidone | Risperidone | 38 | suppressed |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 27 |
| Latanoprost | Latanoprost | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | suppressed |
| Primidone | Primidone | 35 | suppressed |
| Diazepam | Diazepam | 34 | 17 |
| Topiramate | Topiramate | 34 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 33 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Repatha Sureclick | Evolocumab | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 29 | 12 |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 19 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Methenamine Mandelate | Methenamine Mandelate | 26 | suppressed |
| Sotalol | Sotalol Hcl | 26 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 23 |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 15 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 17 | 16 |
| Rexulti | Brexpiprazole | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 15 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Famciclovir | Famciclovir | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Enulose | Lactulose | 13 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Multaq | Dronedarone Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Tenormin | Atenolol | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Tirosint | Levothyroxine Sodium | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,047.14 · 61 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE, Flector, General - Pain Management, JARDIANCE, Kerendia, LEQVIO, Licart, MOUNJARO, Ozempic, PREVNAR 20, REXULTI, Rybelsus, TRELEGY ELLIPTA, Tirosint, Veozah, Wegovy, XIFAXAN, XYOSTED, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error